PAD4-IN-2 是一种 IC50 为 1.94 μM 的不可逆 PAD4 抑制剂,具有高度肿瘤靶向性,可特异性识别肿瘤表面唾液酸并在肿瘤组织中富集,分布于肿瘤细胞胞质及中性粒细胞细胞核中,通过抑制 PAD4-H3cit-NETs (Neutrophil Extracellular Traps) 通路、减少衰老型肿瘤相关中性粒细胞并促进巨噬细胞 M1 型极化,表现出显著的抗肿瘤及抗转移活性,可用于乳腺癌研究。
产品编号: MS-E65932 CAS No.: 2642327-52-2 分子式: C20H23BClN7O6 分子量: 503.70
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
询价
10mg
询价
询价

产品描述

PAD4-IN-2 是一种 IC50 为 1.94 μM 的不可逆 PAD4 抑制剂,具有高度肿瘤靶向性,可特异性识别肿瘤表面唾液酸并在肿瘤组织中富集,分布于肿瘤细胞胞质及中性粒细胞细胞核中,通过抑制 PAD4-H3cit-NETs (Neutrophil Extracellular Traps) 通路、减少衰老型肿瘤相关中性粒细胞并促进巨噬细胞 M1 型极化,表现出显著的抗肿瘤及抗转移活性,可用于乳腺癌研究。

生物实验数据

生物活性 PAD4-IN-2 is an irreversible PAD4 inhibitor with an IC50 of 1.94 μM that exhibits high tumor targeting, specifically recognizes tumor surface sialic acid and accumulates in tumor tissues, distributes in both the cytoplasm of tumor cells and the nuclei of neutrophils, and inhibits the PAD4-H3cit-NETs (Neutrophil Extracellular Traps) pathway, reduces senescent tumor-associated neutrophils, and promotes M1 macrophage polarization, demonstrating significant antitumor and antimetastatic activities and being applicable for breast cancer research.
IC50 & Target

IC50: 1.94 μM (PAD4).

体外研究
(In Vitro)

PAD4-IN-2 (compound 5i) 在比色法检测中能够抑制 PAD4 酶活性 (IC50 = 1.94 μM),并且在 48 h 处理后对 LLC、4T1 细胞及正常 HL7702 细胞的细胞毒性均可忽略不计 (IC50 > 100 μM)。
PAD4-IN-2 (25-100 μM;48 小时) 可有效抑制 4T1 细胞的单克隆增殖,并呈剂量依赖性地抑制其迁移。
PAD4-IN-2 (50-100 μM;1-48 小时) 呈时间依赖性地被 4T1 细胞特异性摄取而不会进入正常的 HL7702 细胞,在电子显微镜下可观察到其诱导细胞线粒体异常收缩并减少表面伪足,并且该化合物可定位于中性粒细胞的细胞核以降低组蛋白 3 瓜氨酸化 (H3cit) 水平,从而抑制中性粒细胞胞外诱捕网 (NETs) 的形成。

Cell Viability Assay

Cell Line: LLC, 4T1, and HL7702 cells
Concentration: 3.125, 6.25, 12.5, 25, 50, and 100 μM
Incubation Time: 48 h
Result: Showed no significant lethal effect on either tumor or normal cells, with an IC50 value greater than 100 μM.

Cell Proliferation Assay

Cell Line: 4T1 cells
Concentration: 25, 50, and 100 μM
Incubation Time: 48 h
Result: Reduced the number of single cell proliferation significantly and effectively inhibited the monoclonal proliferation of tumor cells.

Cell Migration Assay

Cell Line: 4T1 cells
Concentration: 25, 50, and 100 μM
Incubation Time: 48 h
Result: Inhibited tumor cell migration in a dose-dependent manner, and significantly decreased both the number of migrated cells and the migration distance.

Immunofluorescence

Cell Line: 4T1 cells and bone marrow neutrophils
Concentration: 50 μM and 100 μM
Incubation Time: 48 h
Result: Localized to the cytoplasm of tumor cells and the nucleus of neutrophils, decreased intracellular histone 3 citrullination (H3cit) levels, and significantly inhibited the formation of neutrophil extracellular traps (NETs).
体内研究
(In Vivo)

PAD4-IN-2 (compound 5i) (5.04 mg/kg;静脉注射;每天一次,连续 21 天) 在原位 4T1 乳腺癌小鼠模型中能够抑制原发肿瘤生长并抑制肺转移。
PAD4-IN-2 (5.04 mg/kg;腹腔注射;每天一次,连续 7 天) 在 S180 肉瘤小鼠模型中表现出初步的体内抗肿瘤功效。
PAD4-IN-2 (1.01-5.04 mg/kg;静脉注射;每天一次,连续 21 天) 在体内能够减少中性粒细胞胞外诱捕网 (NETs) 的形成,改变肿瘤微环境中的免疫细胞浸润,且未表现出明显的肝毒性或肾毒性。

Animal Model: S180 sarcoma mouse model (Kunming mice)
Dosage: 10 μmol/kg
Administration: Intraperitoneal injection (i.p.), once daily for 7 days
Result: Inhibited tumor growth with an in vivo tumor inhibition rate (TIR) of 49.2%.
Animal Model: Orthotopic 4T1 breast cancer mouse model (BALB/c female mice)
Dosage: 2, 5, and 10 μmol/kg
Administration: Tail vein intravenous injection (i.v.), once daily for 21 days
Result: Reduced primary tumor volume and tumor weight substantially at the dose of 10 μmol/kg.
Suppressed the number of metastatic tumor nodules in the lungs markedly in a dose-dependent manner.
Maintained stable body weight in treated mice throughout the administration period.
Animal Model: Orthotopic 4T1 breast cancer mouse model (BALB/c female mice)
Dosage: 10 μmol/kg
Administration: Tail vein intravenous injection (i.v.), once daily for 21 days
Result: Showed intact alveolar structures and absence of tumor cell lesions in H&E-stained lung sections.
Decreased the number of Ly6G-positive neutrophils and H3cit-positive cells in immunofluorescence-stained tumor sections.
Caused no significant variations in serum levels of Cr, BUN, AST, and ALT compared with the normal saline control group.
Exhibited no apparent histopathological damage or organic lesions in H&E-stained sections of the heart, liver, spleen, and kidney tissues.
Reduced the proportion of aged neutrophils (Naged CD194hi CD62Llo) in tumor tissues.Increased the ratio of M1-type macrophages in tumor tissues.

化学信息

分子量 503.70
分子式 C20H23BClN7O6
CAS No. 2642327-52-2

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础